← board
CAMP
distress 6/10 · elevated risk$3.110%today-56% from 52w high
Lead: Urea Cycle Disorders
Revenue
pre-revenue
Liquidity
$99M
Runway
3.8 yrs
Shares 1y
+158%
Price & events
-33.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-20.3%
1W
-28.7%
1M
-30.0%
3M
-22.4%
6M
+84.0%
1Y
—
2Y
—
5Y
-71.0%
All
Overview
- Market Cap
- $161.49M
- Volume
- 2.69K
- 52 Week Range
- $1.36 – $7.13
- Total Shares
- 51.93M
- Float Shares
- 27.47M
- Short %
- 3.73%
- % Held by Insiders
- 13.07%
- % Held by Institutions
- 86.72%
- RVOL
- 0.01x
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- 2025trial initiationsecondaryCMP-SYNGAP1 · Initiation of GLP toxicology studiesSEC 8-K
- 2H 2025readoutPhase 1CMP-CPS-001 · Topline results from multiple ascending dose (MAD) portion of Phase 1 trialSEC 8-K
- 2025-12-17partnershipCAMP4 enters R&D collaboration and exclusive license agreement with GSK for ASO therapeutics, receiving $17.5M upfront and up to $440M in milestones.SEC 8-K
- May 16, 2025conferencedata presentationsecondaryPresented translational data from SYNGAP1 program and preclinical/safety data from UCD program.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $9 (+176% upside) · 6 analysts
- 2026-06-16JP MorganNeutral → Overweight
- 2026-06-10Chardan CapitalBuy
- 2026-04-14Rodman & RenshawBuy
- 2026-04-02Leerink PartnersOutperform
- 2025-10-02Cantor FitzgeraldOverweight
- 2025-09-16JP MorganOverweight → Neutral
Competitors — Urea Cycle Disorders
- none identified
Recent news
- 2026-07-17CAMP4 New Hire Gets Option on 8,000 Shares at $4.21 - Stock Titan
- 2026-06-19CAMP4 lures 3 new hires with 39,000 stock options - Stock Titan
- 2026-06-16JPMorgan upgrades CAMP4 Therapeutics stock rating on CMP-002 potential - Investing.com
- 2026-06-12Camp4 Therapeutics (CAMP) director awarded 28,000 stock options at $4.34 strike - Stock Titan
- 2026-04-17Three new CAMP4 hires get stock options at $4.59 a share - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.